UI Hospitals and Clinics
Study to Determine Appropriate Dose of Medication for Patients with diagnosed with Recurring Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Who can apply: People diagnosed with recurring ovarian, primary peritoneal, or fallopian tube cancer.
Purpose: To determine the appropriate dose of an experimental drug, evaluate side effects when combined with other drugs, and test samples of tumor tissue (if available from a previous surgery or biopsy).
Drugs: ABT-888 (Veliparib), carboplatin and pegylated liposomal doxorubicin (PLD).
Number of participants: 10.
Sharon Stockman, 319-356-2015
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.